ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83 rd American Academy of ...

February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

2 NOT FOR UK USE NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 ...

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

The global Clinical Trial Services Market, valued at US$60.76 billion in 2024, is forecasted to grow at a robust CAGR of 8.9% ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

That’s according to the team at LEO Pharma, who spoke to pharmaphorum as part of our Towards Patient Centricity series. Ensuring people get the care – and the drug products – they need to ...